Detecting neoplasm

Patent metadata

Field	Value
Publication number	US-11530449-B2
Application number	US-202016738706-A
Country	US
Kind code	B2
Filing date	Jan 9, 2020
Priority date	Feb 15, 2008
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

First claim

What is claimed is:

1. A system, comprising:
(a) reagents for extracting genomic DNA from a biological sample of a human individual suspected of having precancer or colorectal cancer;
(b) primers specific for K-ras, wherein the primers specific for K-ras are selected from SEQ ID NOs: 2, 3, 4, 5, 6, 7 and 8;
(c) reagents sufficient for measuring the methylation level of one or more CpG sites in BMP3,
wherein the reagents sufficient for measuring the methylation level of one or more CpG sites in BMP3 comprise reagents sufficient for conducting one or more of methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, and bisulfite genomic sequencing PCR,
wherein the reagents sufficient for conducting one or more of methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, and bisulfite genomic sequencing PCR comprise BMP3 specific primers and a bisulfite reagent; and

(d) a stool stability buffer.

2. The system of claim 1 , wherein the biological sample is a stool sample.

3. The system of claim 1 , further comprising reagents sufficient for measuring a K-ras mutation score.

4. The system of claim 3 , wherein the reagents sufficient for measuring a K-ras mutation score comprises reagents sufficient for conducting
a digital melt curve analysis, and/or
a quantitative allele-specific PCR.

5. The system of claim 1 , wherein the bisulfite reagent is sodium bisulfite.

6. The system of claim 1 , further comprising reagents sufficient for converting unmethylated cytosine residues to uracil residues within said biological sample while leaving 5-methylcytosine residues unchanged.

7. The system of claim 1 , wherein the stool stability buffer is a DNA stabilization buffer.

8. The system of claim 1 , wherein the primers specific for K-ras are specific for a K-ras mutation at amino acid number 12.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Taylor William R
• Harrington Jonathan J
• Quint Patrick S
• Zou Hongzhi
• Bergen Iii Harold R
• Smith David I
• Ahlquist David A

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57535

  of the large intestine, e.g. colon, rectum or anus · CPC title

• G01N33/57525

  of the liver or pancreas · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Y304/2107

  Pancreatic endopeptidase E (3.4.21.70) · CPC title